Comments
Commented by Nico Popp on June 4th, 2025 | 07:10 CEST
Rethinking country risk! BHP Group, Commerzbank, AJN Resources
Commodities are in demand like never before! Gold is trading above the USD 3,000 mark, and the World Bank forecasts that cobalt consumption will rise to 344,000 tons by 2030 - equivalent to annual growth of around 9.6%. Over 70% of cobalt comes from the Democratic Republic of Congo – a country that is repeatedly viewed critically in Western media. But what are the real disadvantages of this location? Which mining jurisdictions are safe? Where are the returns?
ReadCommented by André Will-Laudien on June 4th, 2025 | 07:00 CEST
With gold over USD 3,400 - 100% gains in no time: Gerresheimer, Desert Gold, Hensoldt, and RENK
Rumors about Jerome Powell's resignation were circulating at the beginning of the week. Described as very "hawkish," meaning he strictly aligns interest rates with inflation, he is an uncomfortable contemporary for President Donald Trump. The US administration needs a lot of money to get the outdated infrastructure and the entire economy back on track. Numerous campaign promises for a flourishing America can only be fulfilled by the flamboyant frontman if sufficient funds are available. This is a difficult undertaking due to the very high level of government debt. The credit rating agency Moody's is not intimidated by the president's threats and recently downgraded the US credit rating by one notch to AA1. Triple-A status is now history. This is a perfect setup for gold, with the precious metal rising again to over USD 3,400. Where are the opportunities for investors?
ReadCommented by Fabian Lorenz on June 3rd, 2025 | 07:20 CEST
A bombshell and a buying opportunity! BioNTech, Bayer, and AI stock NetraMark
Bombshell news from BioNTech. The Company has announced a collaboration for its cancer pipeline - billions in revenue are on the horizon. The stock has surged significantly. Are there other exciting buying opportunities in the biotech and pharma sectors right now? US politics have recently dampened industry sentiment. The Trump administration wants to lower drug prices. One potential beneficiary is NetraMark, as this AI gem helps industry cut development costs and timelines. In addition, takeover speculation could drive the stock in the second half of the year. And what is Bayer doing? The stock has outperformed the DAX in 2025. Are there reasons to consider buying?
ReadCommented by Fabian Lorenz on June 3rd, 2025 | 07:10 CEST
SHOCK for RENK, "BUY" rating for Novo Nordisk, and PanGenomic Health follows in the footsteps of Hims & Hers
Shock for RENK & Co.! Yesterday afternoon, news broke that the EU plans to tap into the billions in profits made by defense companies. After all, these companies are facing a golden age. The shares ended their record run yesterday. The alternative medicine and dietary supplements sector is currently experiencing a boom in the US. PanGenomic Health wants a piece of that multi-billion-dollar market. The newcomer is launching an AI-based app offering recommendations, a marketplace, and diagnostics. The rollout will begin this summer. Anyone who missed out on the 800% gains at Hims & Hers should take a look at this newcomer. Novo Nordisk is a core investment in the pharmaceutical sector. However, expectations for the blockbuster drug Ozempic were likely set too high. After the stock's crash, things are now looking better again.
ReadCommented by Armin Schulz on June 3rd, 2025 | 07:05 CEST
The Pentagon Connection: How Almonty Industries is leveraging military demand for tungsten to generate record profits
Global supply chains for critical minerals are facing a turning point. As China curbs its exports, Almonty Industries is stepping into the spotlight. Through strategic moves, the tungsten specialist is catapulting itself into a key position for Western industry. This year's latest developments - from billion-dollar contracts to relocation to the US - point to enormous growth potential. For investors, this could become one of the most exciting commodity stories of the year.
ReadCommented by Nico Popp on June 3rd, 2025 | 07:00 CEST
Get more out of your money! Scaling is happening here: Apple, Credissential, and Shopify
For years, banks have controlled how we manage our money. The structures surrounding payment flows and investments are still quite rigid. But the old structures are breaking up and offering new potential - for digitally savvy users and investors alike. We show you what is happening in fintech and e-commerce and how investors can benefit.
ReadCommented by Fabian Lorenz on June 2nd, 2025 | 07:15 CEST
Alarm bells ringing for rare earths and record highs for hydrogen! Hensoldt, Plug Power, Mercedes, and BMW partner European Lithium
Rare earths are increasingly being used as a weapon in geopolitics. "The last remaining stocks will likely be used up within four to six weeks. Then parts of production will have to be shut down," warns Christian Grimmelt of the consulting firm Berylls by AlixPartners in Wirtschaftswoche. This could benefit European Lithium's stock. The Company not only aims to supply lithium to BMW but is also developing a rare earths project in Greenland. Is the defense industry also affected by the shortage of raw materials? Perhaps. For now, the FOMO rally is driving defense stocks to new all-time highs. But caution is advised: according to analysts, Hensoldt shares, for example, have a 30% downside risk. Plug Power, on the other hand, has had to cope with many setbacks in recent months. Its shares are at rock bottom. Could a milestone in its home market bring about a turnaround?
ReadCommented by Armin Schulz on June 2nd, 2025 | 07:10 CEST
Bayer, Vidac Pharma, Evotec – Grab your share of the USD 866 billion oncology jackpot
Oncology is undergoing an unprecedented revolution. With a projected market volume of USD 866 billion by 2034 and annual growth of 11%, AI-driven diagnostics, personalized gene therapies, and precision medicine are driving this boom. Rising disease rates worldwide are fueling investment, while technological leaps are making therapies more effective and opening up high-return opportunities. Three players aim to leverage this explosive momentum for their profitable future: Bayer, Vidac Pharma, and Evotec.
ReadCommented by André Will-Laudien on June 2nd, 2025 | 07:05 CEST
Madness: New tariffs - no, yes, or maybe not? Trump moves thyssenkrupp, Power Metallic, RENK, and Plug Power
The stock markets have rarely seen such volatility. At this point, there are multiple shifts in direction on every trading day, triggered by the latest headlines from the White House. Last week was almost entirely about tariffs, with Putin's war and Trump's peace promises already forgotten. The world continues to live in uncertainty due to the prevailing war scenario, with no stone left unturned. This environment makes it clear: secure supply routes for raw materials will be essential in the coming period. In the defense industry in particular, metal shortages could become a showstopper. Investors can benefit from the current trends through careful selection as Western industrialized nations are stepping on the gas. Where are the big return generators hiding?
ReadCommented by Stefan Feulner on June 2nd, 2025 | 07:00 CEST
Rheinmetall, Volatus Aerospace, C3.ai – Upgrades and explosive results
The quarterly reporting season is drawing to a close, with chip giant Nvidia being the last of the Magnificent 7 stocks to present its figures. Analysts' ambitious targets were once again smashed, but uncertainties surrounding the trade war between China and the US are dampening the outlook for the industry leader. In contrast, uncertainty about the geopolitical situation continues to boost business for defense companies, which are receiving ever-higher price targets from analysts.
Read